Ulcerative Colitis: A Streamlined Overview of Pathophysiology and Treatment Strategies

Ulcerative colitis is a chronic inflammatory disorder of the colon that progresses through alternating periods of active flare-ups and remission. The condition primarily affects the lining of the large intestine, beginning in the rectum and often spreading upward through the colon. Several factors can increase susceptibility, including prior bacterial infections such as Salmonella or Campylobacter, as well as a family history of inflammatory bowel disease. Diagnosis is typically guided by clinical symptoms such as rectal bleeding, tenesmus, and an urgent need to defecate. Confirmation is obtained through endoscopic evaluation, which usually reveals continuous mucosal inflammation starting at the rectum and extending proximally, depending on disease severity. Fecal biomarkers may also be utilized to monitor inflammation levels and anticipate relapses. Although ulcerative colitis can severely impact young, otherwise healthy individuals, its underlying causes remain only partially understood. This uncertainty has encouraged diverse theories regarding its development and treatment. Despite significant advances in therapy, the condition continues to pose both clinical and psychological challenges. Treatment strategies are primarily aimed at controlling inflammation and maintaining remission. Commonly prescribed medications include 5-aminosalicylic acid compounds and corticosteroids, with the choice of agent and delivery method based on disease extent and severity. Experimental options such as fecal microbiota transplantation are under investigation, while complementary interventions like probiotics and curcumin have produced variable results. In cases of severe or treatment-resistant disease, surgical management may become necessary. Because prolonged inflammation and immunosuppressive therapy can elevate the risk of colorectal cancer, patients require vigilant preventive care and regular screening to detect complications early.